Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) (PREVAIL)
Type 2 Diabetes

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring type 2 diabetes, beta-cell function, GLP-1, insulin
Eligibility Criteria
Inclusion Criteria:
- Men and women between the ages of 30 and 80 years inclusive
- T2DM diagnosed by a physician ≤7 years prior to enrolment
- On 0-2 anti-diabetic medications, with no change in dose/regimen in the preceding 4 weeks
- A1c at screening between 5.5% and 9.0% inclusive if on anti-diabetic medications, or between 6.0% and 9.5% inclusive if on no oral anti-diabetic medication
- BMI ≥ 23 kg/m2
- Negative pregnancy test at recruitment for all women with childbearing potential
Exclusion Criteria:
- Current anti-diabetic treatment with insulin or a glucagon-like peptide-1 (GLP-1) agonist
- Type 1 diabetes or secondary forms of diabetes
- History of hypoglycemia unawareness or severe hypoglycemia requiring assistance
- Hypersensitivity to insulin, exenatide, or the formulations of these products
- Renal dysfunction as evidenced by estimated glomerular filtration rate (eGFR)<30 ml/min by Modification of Diet in Renal Disease (MDRD) formula
- History of pancreatitis
- Family or personal history of Multiple Endocrine Neoplasia type 2 (MEN-2) or familial medullary thyroid carcinoma (MTC)
- Personal history of non-familial medullary thyroid carcinoma (MTC)
- Malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy within the previous 5 years (with the exception of basal cell skin cancer)
- Unwillingness to perform capillary glucose monitoring at least 4 times a day during treatment
- Pregnancy or unwillingness to use reliable contraception. Women should not be planning pregnancy for the duration of the study or the first 3 months after the study. Reliable contraception includes birth control pill, intra-uterine device, abstinence, tubal ligation, partner vasectomy, or condoms with spermicide.
- Any factor likely to limit adherence to the protocol, in the opinion of investigator
Sites / Locations
- Mount Sinai Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Active Comparator
Basal insulin and exenatide
Basal insulin only
Basal Insulin and bolus insulin
Participants in this arm will undergo an 8-week course of treatment with exenatide and insulin glargine. Exenatide will be initiated at 5ug subcutaneous (sc) bid (before breakfast and before dinner) for the first 4 weeks, followed by 10ug bid for the next 4 weeks. Glargine sc injection at bedtime will be titrated to fasting glucose.
Participants in this arm will undergo an 8-week course of treatment with glargine sc injection at bedtime, titrated to target fasting glucose.
Participants in this arm will undergo an 8-week course of multiple daily insulin injection therapy, consisting of titrated basal insulin glargine at bedtime and insulin lispro before each meal.